Kazia Therapeutics (KZIA) - Quarterly EPS earnings growth

Official company branding of Kazia Therapeutics Ltd (KZIA)

Kazia Therapeutics (KZIA) is attracting top oncology experts by offering them global scientific collaboration. This quarterly earnings per share chart clearly demonstrates the financial dynamics, with the indicator settling at 67.80. International trials of targeted therapies ensure risk mitigation. Orphan drug status from the FDA creates a closed market niche, retaining patients within the paxalisib drug trials.

Kazia Therapeutics Limited (KZIA) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/18/2026

Analytical breakdowns for Kazia Therapeutics

- market value and analyst target forecast:
Fundamental company analysis:Kazia Therapeutics Ltd, KZIA
Manufactured product of Kazia Therapeutics

This metric measures earnings per share (EPS) dynamics in real time, eliminating gaps between quarterly reports to assess the fundamental resilience of the business. The current quarterly EPS growth rate of 67.80 reflects the financial efficiency of Kazia Therapeutics (KZIA), which converts the expertise of recruited oncologists and clinical phase experts into company capitalization.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Corbus Pharma CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months CANF (Can-Fite BioPharma, Ltd.)|APRE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc